Geron Corp - GERN STOCK NEWS

Geron Corporation (NASDAQ: GERN) announced key additions to its senior commercial leadership team as it prepares for the anticipated launch of imetelstat, a first-in-class telomerase inhibitor, in the U.S. for lower risk myelodysplastic syndromes (MDS) in the first half of 2024, pending regulatory approvals. The company reported positive Phase 3 clinical trial results and plans to submit a New Drug Application (NDA) in mid-2023 and a Marketing Authorization Application (MAA) in the EU in late 2023. This strategic hiring aims to ensure successful market access and commercialization efforts.

Geron Corporation (NASDAQ: GERN) has successfully completed a public offering of common stock and pre-funded warrants, generating $227.8 million in gross proceeds. The offering included 68,007,741 shares at a price of $2.45 per share, with an additional 25,000,000 pre-funded warrants. After expenses, the net proceeds are estimated to be around $213.3 million. Geron plans to utilize these funds primarily for the potential commercial launch of imetelstat in the U.S. for lower risk MDS and for general corporate purposes.

Geron Corporation (Nasdaq: GERN) announced an upsized underwritten public offering of 55,876,297 shares at $2.45 each and pre-funded warrants for 25,000,000 shares at $2.449 each. The expected gross proceeds are approximately $198.1 million, aimed at funding preparatory activities for the potential U.S. commercial launch of imetelstat in lower risk MDS. The offering is set to close around January 10, 2023, pending customary conditions.

Geron Corporation (Nasdaq: GERN) announced a proposed public offering of $175 million in common stock, with an option for underwriters to buy an additional 15%. The offering is dependent on market conditions and does not guarantee completion. Goldman Sachs & Co. LLC and Stifel serve as joint book-running managers. A preliminary prospectus will be filed with the SEC. Geron focuses on developing therapies for hematologic malignancies, primarily its investigational telomerase inhibitor, imetelstat.

Geron Corporation (NASDAQ: GERN) announced positive results from its IMerge Phase 3 trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The trial met its primary endpoint of 8-week transfusion independence (TI) and a key secondary endpoint at 24 weeks, demonstrating significant benefits compared to placebo. Notably, the median TI duration was nearly one year for 8-week responders and 1.5 years for 24-week responders. No new safety signals were observed, and the company plans for U.S. and EU regulatory submissions in 2023, aiming for a commercial launch in 2024.

Geron Corporation (NASDAQ: GERN) will host a conference call on January 4, 2023, at 8:00 a.m. ET to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat for lower risk myelodysplastic syndromes (MDS). Investors can access the call via a live webcast on Geron’s website. Imetelstat is a first-in-class telomerase inhibitor aimed at treating hematologic malignancies. This trial represents a significant step in evaluating the drug's potential to impact patients' lives.

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options totaling 867,130 shares to newly hired employees as an inducement for employment. The options were issued on December 21, 2022, at an exercise price of $2.08 per share, matching the stock's closing price on that day. These options include 750,000 shares with a four-year vesting period and 117,130 shares that vest upon achieving specific regulatory milestones. All options comply with Nasdaq rules and the terms of Geron's 2018 Inducement Award Plan.

Geron Corporation (NASDAQ: GERN) reported promising results from the IMerge Phase 2 trial of imetelstat, a telomerase inhibitor for lower risk myelodysplastic syndromes (MDS). The trial showed that 29% of patients achieved durable transfusion independence for over one year, with a median duration of 1.8 years. Additionally, 33% of patients previously treated with luspatercept also reached one-year transfusion independence. There were notable increases in hemoglobin levels and decreases in SF3B1 variant allele frequency correlated with treatment, indicating potential disease modification. Phase 3 results are expected in January 2023.

Geron Corporation (Nasdaq: GERN) granted non-statutory stock options to purchase 566,890 shares of common stock to new employees as an employment inducement. The options, issued at an exercise price of $2.24 per share, equal the closing stock price on the grant date of November 16, 2022. Notably, 470,000 shares vest over four years, while 96,890 shares vest upon achieving specific regulatory milestones. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan aimed at fostering talent for ongoing clinical trials evaluating its telomerase inhibitor, imetelstat.